Clinical trials: insulin glargine
Diabetes Mellitus
Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy
Type I diabetes (T1DM) is the second most common chronic illness effecting children in the USA. Worldwide, Type I diabetes is increasing in incidence, and its underlying etiology remains elusive.
- Trial name
- ktpump (NCT00574405)
- Testing
- MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Cystic Fibrosis Related Diabetes
Insulin Glargine Vs Standard Insulin Therapy
This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
- Trial name
- NCT00222521
- Testing
- Glargine insulin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Minnesota
Type 1 Diabetes
To Evaluate add-on Effect of Nisha-Amalaki Tablets Along With Insulin on Glycemic Control in Type 1 Diabetes Patients (RCTNA)
Type-I diabetes mellitus (T1DM) is an autoimmune condition, in which the pancreas reduces/stops insulin production. Patients with T DM have to take insulin injections with every meal and also usually a long-acting preparation.
- Trial name
- NCT06487598
- Testing
- inj insulin to one group, Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Hirabai Cowasji Jehangir Medical Research Institute
Type 2 Diabetes (T2DM)
Influence of Gut Microbiota on the Development of Type 2 Diabetes Mellitus and Personalization of Diabetes-lowing Therapy
An observational, single-center, prospective study was conducted to examine the impact of CM on the development of T2DM and the personalization of initial SST in patients with newly diagnosed T2DM who had not previously received…
- Trial name
- GM (NCT07627048)
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Pirogov Russian National Research Medical University
Diabetes
Comparison Study of Insulin Glargine and NPH Insulin
This study will compare the safety, effectiveness, and cost of two different types of long-acting insulin.
- Trial name
- NCT01854723
- Testing
- Switching to NPH insulin, Continuation of insulin glargine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Providence Health & Services
Type 1 Diabetes
New Onset Type 1 Diabetes: Role of Exenatide
There are many recent advances in insulin treatment of type 1 diabetes, however after a meal sugars are always a concern. There is a drug Exenatide (Byetta) which is FDA approved to treat people with type 2 diabetes which helps…
- Trial name
- NCT01269034
- Testing
- Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Type 1 Diabetes
Lantus in the Treatment of Type 1 Diabetes Children
In this study, we plan to examine the difference in effect on blood glucose control in patients who will be on either conventional insulin therapy (i.e.
- Trial name
- NCT00206401
- Testing
- Lantus and short acting analogs Vs NPH and short acting analogs
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Baylor College of Medicine
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes
This trial was conducted in Europe. The aim of this clinical trial was to look into the concentration of NN1250 (insulin degludec/insulin 454) in the blood after one injection of NN1250 in children, adolescents and adults with…
- Trial name
- NCT01030926
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH
To determine whether using a long-acting insulin analog at the time of diagnosis, instead of intermediate-acting insulin, affects the rate of loss of the body's ability to make insulin in children with newly diagnosed type 1…
- Trial name
- NCT00564018
- Testing
- Insulin detemir, Glargine, NPH
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Type 2
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin icodec to different daily insulins in people with type 2 diabetes. The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily.
- Trial name
- ONWARDS 5 (NCT04760626)
- Testing
- Insulin icodec, Insulin Glargine 100U/mL, Insulin Degludec
- Where
- 311 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,085 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus With Hypoglycemia, type1diabetes
Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.
Background: Achieving glycemic control without risking hypoglycemia imposes a major challenge in the management of toddlers and preschool children with Type 1 diabetes(T1D).
- Trial name
- NCT04664764
- Testing
- Degludec, Glargine, NPH insulin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Diabetes Mellitus, Type I
Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs
The aim of this study is to evaluate the variations in pharmacokinetic and pharmacodynamic properties of rapid-acting insulin analogs when given as a bolus by subcutaneous insulin infusion pump as typically encountered in the…
- Trial name
- PK/PD (NCT00652288)
- Testing
- Insulin analogs (Lispro and Aspart), Insulin analogs (Aspart and Detemir), Insulin analogs (Lispro and Glargine)
- Volunteers
- 36 people
- Sponsor
- Yale University
Prediabetes, Type 2 Diabetes
RISE Pediatric Medication Study
The RISE Pediatric Medication Study is a 2-arm, 4-center, clinical trial of children with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell…
- Trial name
- RISE Peds (NCT01779375)
- Testing
- Metformin, Glargine
- Where
- 4 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- RISE Study Group
Diabetes Type 1
Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents
A randomized, crossover, open study in order to compare treatment satisfaction with insulin Glargine plus insulin Apidra Vs NPH insulin plus insulin Apidra in newly diagnosed children and adolescents with type 1 diabetes.
- Trial name
- NCT00925977
- Testing
- insulin Glargine + Insulin Apidra, Insulin NPH + Insulin Apidra: Active Comparator
- Where
- 4 sites in Israel
- Volunteers
- 44 people
- Sponsor
- Rabin Medical Center
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes
The management goals of diabetic ketoacidosis (DKA) in the pediatric type 1 diabetes (T1DM) population are fluid and electrolyte repletion, insulin administration, and correction of acidosis in order to stabilize the patient.
- Trial name
- NCT02548494
- Testing
- Glargine, IV insulin, Electrolyte Correction
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Chattanooga-Hamilton County Hospital Authority
Diabetes Mellitus, Type II
Comparison of Apidra to Regular Insulin in Hospitalized Patients
The purpose of this study is to compare Apidra (a rapid acting insulin analogue) with Regular insulin (fast acting) in addition to the use of long acting insulin Glargine in hospitalized patients in terms of efficacy and safety…
- Trial name
- Apidra (NCT00528918)
- Testing
- Glulisine (Apidra)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Carl T. Hayden VA Medical Center
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® INHALE-1 Study in Pediatrics
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine…
- Trial name
- INHALE-1 (NCT04974528)
- Testing
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Mannkind Corporation
Type I Diabetes
Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh
This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Bangladesh
- Trial name
- NCT06674135
- Testing
- biosimilar insulin glargine
- Where
- Bangladesh
- Volunteers
- 202 people
- Sponsor
- Life for a Child Program, Diabetes Australia
Leukemia, Lymphoma
Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)
The goal of this clinical research study is to learn if intense management and control of blood sugar levels during treatment for acute lymphocytic leukemia, Burkitts lymphoma, or lymphoblastic lymphoma will result in decreased…
- Trial name
- NCT00500240
- Testing
- Insulin Glargine, Insulin Aspart
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Type 1 Diabetes Mellitus
Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
Primary Objective: 6 To assess the efficacy of insulin glargine given once daily (QD) on glycosylated hemoglobin (HbA1c) levels over a period of 24 weeks in children with type 1 diabetes mellitus (T1DM) aged at least 6 years to…
- Trial name
- Lantus-P-CN (NCT01223131)
- Testing
- Insulin glargine (HOE901), NPH insulin
- Where
- 10 sites in China
- Volunteers
- 162 people
- Sponsor
- Sanofi